These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32152170)

  • 1. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial.
    Efron D; Taylor K; Payne JM; Freeman JL; Cranswick N; Mulraney M; Prakash C; Lee KJ; Williams K
    BMJ Open; 2020 Mar; 10(3):e034362. PubMed ID: 32152170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability.
    Efron D; Freeman JL; Cranswick N; Payne JM; Mulraney M; Prakash C; Lee KJ; Taylor K; Williams K
    Br J Clin Pharmacol; 2021 Feb; 87(2):436-446. PubMed ID: 32478863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
    Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
    Trials; 2024 May; 25(1):293. PubMed ID: 38693590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
    Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
    BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol (CBD) and Δ
    Suraev A; Grunstein RR; Marshall NS; D'Rozario AL; Gordon CJ; Bartlett DJ; Wong K; Yee BJ; Vandrey R; Irwin C; Arnold JC; McGregor IS; Hoyos CM
    BMJ Open; 2020 May; 10(5):e034421. PubMed ID: 32430450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain.
    Pike CK; Kim M; Schnitzer K; Mercaldo N; Edwards R; Napadow V; Zhang Y; Morrissey EJ; Alshelh Z; Evins AE; Loggia ML; Gilman JM
    BMJ Open; 2022 Sep; 12(9):e063613. PubMed ID: 36123113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
    Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
    Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial.
    Bawa Z; McCartney D; Bedoya-Pérez M; Lau NS; Fox R; MacDougall H; McGregor IS
    BMJ Open; 2024 Mar; 14(3):e082927. PubMed ID: 38531572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).
    Good P; Haywood A; Gogna G; Martin J; Yates P; Greer R; Hardy J
    BMC Palliat Care; 2019 Dec; 18(1):110. PubMed ID: 31810437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study.
    Hendricks O; Andersen TE; Christiansen AA; Primdahl J; Hauge EM; Ellingsen T; Horsted TI; Bachmann AG; Loft AG; Bojesen AB; Østergaard M; Lund Hetland M; Krogh NS; Roessler KK; Petersen KH
    BMJ Open; 2019 Jun; 9(6):e028197. PubMed ID: 31167870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.
    Müller AR; den Hollander B; van de Ven PM; Roes KCB; Geertjens L; Bruining H; van Karnebeek CDM; Jansen FE; de Wit MCY; Ten Hoopen LW; Rietman AB; Dierckx B; Wijburg FA; Boot E; Brands MMG; van Eeghen AM
    BMC Psychiatry; 2024 Jan; 24(1):23. PubMed ID: 38177999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
    Narayan AJ; Downey LA; Rose S; Di Natale L; Hayley AC
    J Clin Sleep Med; 2024 May; 20(5):753-763. PubMed ID: 38174873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
    van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP
    BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
    Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
    BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.